Gene
FAF2
| Entrez Gene ID | 23197 (See on NCBI) |
| Description | Fas associated factor family member 2 |
| Gene Synonyms | ETEA, UBXD8, UBXN3B |
| Node consisting of this Gene | FAF2 UBXD8 |
Networks including this gene
| GSE10063_top8000 - GSE10063 - SiGN-BN NNSR | Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia |
| GSE10072_top8000 - GSE10072 - SiGN-BN NNSR | Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival |
| GSE10320_top8000 - GSE10320 - SiGN-BN NNSR | Predicting Relapse in Favorable Histology Wilms Tumor Using Gene Expression |
| GSE10797_top8000 - GSE10797 - SiGN-BN NNSR | Transcriptomes of breast epithelium and stroma in normal reduction mammoplasty and invasive breast cancer patients. |
| GSE10810_top8000 - GSE10810 - SiGN-BN NNSR | Gene expression signatures in breast cancer distinguish phenotype charact., histological subtypes, and tumor invasivness |
| GSE11121_top8000 - GSE11121 - SiGN-BN NNSR | The humoral immune system has a key prognostic impact in node-negative breast cancer |
| GSE11482_top8000 - GSE11482 - SiGN-BN NNSR | Rhabdoid Tumor: Gene Expression Clues to Pathogenesis and Potential Therapeutic Targets |
| GSE11582_top8000 - GSE11582 - SiGN-BN NNSR | Genetic Analysis of Human Traits In-Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines |
| GSE11729_top8000 - GSE11729 - SiGN-BN NNSR | H1299 EGF and Iressa stimulation |
| GSE12093_top8000 - GSE12093 - SiGN-BN NNSR | The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy |
| GSE12428_top8000 - GSE12428 - SiGN-BN NNSR | Current smoking-specific gene expression signature in bronchial epithelium is enhanced in squamous cell lung cancer |
| GSE12453_top8000 - GSE12453 - SiGN-BN NNSR | Origin and pathogenesis of lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis |
| GSE12460_top8000 - GSE12460 - SiGN-BN NNSR | Expression profiling of neuroblastic tumors |
| GSE12470_top8000 - GSE12470 - SiGN-BN NNSR | Gene expression profiles of serous ovarian cancer samples |
| GSE12472_top8000 - GSE12472 - SiGN-BN NNSR | A COPD-related gene expression signature in squamous cell lung cancer |
| GSE12682_top8000 - GSE12682 - SiGN-BN NNSR | Expression data from Human Kidney (HK) samples |
| GSE13009_top8000 - GSE13009 - SiGN-BN NNSR | MCF7 EGF, HRG stimulation |
| GSE13168_top8000 - GSE13168 - SiGN-BN NNSR | Effects of glucocorticoids and Protein Kinase A on growth factor- and 1beta- regulated gene |
| GSE13591_top8000 - GSE13591 - SiGN-BN NNSR | Integrated genomics approach to detect allelic imbalances in multiple myeloma |
| GSE13601_top8000 - GSE13601 - SiGN-BN NNSR | Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators |
| GSE13898_top8000 - GSE13898 - SiGN-BN NNSR | Robust prognostic biomarkers for EAC identified by systems-level characterization of tumor transcriptome |
| GSE13996_top8000 - GSE13996 - SiGN-BN NNSR | Molecular profiling of classical Hodgkin’s lymphoma tissues |
| GSE14208_top8000 - GSE14208 - SiGN-BN NNSR | Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy |
| GSE14210_top8000 - GSE14210 - SiGN-BN NNSR | Expression data from human endoscopic biopsy samples |
| GSE14764_top8000 - GSE14764 - SiGN-BN NNSR | A Prognostic Gene Expression Index in Ovarian Cancer |
| GSE14786_top8000 - GSE14786 - SiGN-BN NNSR | Gene expression analysis of cancer-related fatigue in whole blood from breast cancer survivors |
| GSE14879_top8000 - GSE14879 - SiGN-BN NNSR | Gene expression study of anaplastic large cell lymphomas: cellular origin, pathogenesis and relation to Hodgkin lymphoma |
| GSE14925_top8000 - GSE14925 - SiGN-BN NNSR | Expression data from Non small cell lung cancer cell lines |
| GSE15212_top8000 - GSE15212 - SiGN-BN NNSR | Identification and validation of NOL5A and RPS2 as potential therapeutic targtes in colorectal cancer |
| GSE15395_top8000 - GSE15395 - SiGN-BN NNSR | HCT116 tumor cells treated with a CDK inhibitor |
| GSE15852_top8000 - GSE15852 - SiGN-BN NNSR | Expression data from human breast tumors and their paired normal tissues |
| GSE15966_top8000 - GSE15966 - SiGN-BN NNSR | Gene expression signature predictive of rapid response to imatinib mesylate in Gastrointestinal Stromal Tumor (GIST) |
| GSE16382_top8000 - GSE16382 - SiGN-BN NNSR | Expression data from complex genetic sarcomas |
| GSE16446_top8000 - GSE16446 - SiGN-BN NNSR | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| GSE16581_top8000 - GSE16581 - SiGN-BN NNSR | Genomic landscape of meningiomas: gene expression |
| GSE17764_top8000 - GSE17764 - SiGN-BN NNSR | Expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients |
| GSE17920_top8000 - GSE17920 - SiGN-BN NNSR | Expression data of diagnostic biopsy samples from Hodgkin lymphoma patients |
| GSE17951_top8000 - GSE17951 - SiGN-BN NNSR | Gene expression analysis of prostate cancer samples using Affymetrix U133Plus2 array |
| GSE18520_top8000 - GSE18520 - SiGN-BN NNSR | Whole-genome oligonucleotide expression analysis of papillary serous ovarian adenocarcinomas |
| GSE18842_top8000 - GSE18842 - SiGN-BN NNSR | Gene expression analysis of human lung cancer and control samples |
| GSE18864_top8000 - GSE18864 - SiGN-BN NNSR | Tumor expression data from neoadjuvant trial of cisplatin monotherapy in triple negative breast cancer patients |
| GSE19027_top8000 - GSE19027 - SiGN-BN NNSR | Antioxidant response gene expression in the bronchial airway epithelial cells of smokers at risk for lung cancer |
| GSE19069_top8000 - GSE19069 - SiGN-BN NNSR | Molecular signatures in peripheral T-cell lymphoma (PTCL) |
| GSE19417_top8000 - GSE19417 - SiGN-BN NNSR | Human esophageal adenocarcinomas |
| GSE19494_top8000 - GSE19494 - SiGN-BN NNSR | Subcutaneous adipose tissue (SAT) gene expression patterns between weight control and regaining weight subjects |
| GSE19784_top8000 - GSE19784 - SiGN-BN NNSR | Gene expression profiling of multiple myeloma patients included in the HOVON65/GMMG-HD4 trial |
| GSE19804_top8000 - GSE19804 - SiGN-BN NNSR | Genome-wide screening of transcriptional modulation in non-smoking female lung cancer in Taiwan |
| GSE20181_top8000 - GSE20181 - SiGN-BN NNSR | Letrozole (Femara) early and late responses to treatment |
| GSE20189_top8000 - GSE20189 - SiGN-BN NNSR | A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma |
| GSE20194_top8000 - GSE20194 - SiGN-BN NNSR | MAQC-II Project: human breast cancer (BR) data set |
| GSE20271_top8000 - GSE20271 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients |
| GSE2034_top8000 - GSE2034 - SiGN-BN NNSR | Breast cancer relapse free survival |
| GSE21501_top8000 - GSE21501 - SiGN-BN NNSR | A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma |
| GSE2294_top8000 - GSE2294 - SiGN-BN NNSR | A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor-Positive Tumors |
| GSE23036_top8000 - GSE23036 - SiGN-BN NNSR | Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma |
| GSE23553_top8000 - GSE23553 - SiGN-BN NNSR | Gene expression changes with induction of in-vitro platinum-resistance in ovarian cancer cell lines. |
| GSE23806_top8000 - GSE23806 - SiGN-BN NNSR | Expression data of glioblastoma stem-like (GS) cell lines, conventional glioma cell lines and primary tumors |
| GSE23878_top8000 - GSE23878 - SiGN-BN NNSR | Genome Wide Expression Analysis of Middle Eastern Colorectal Cancer Reveals FOXM1 as a Novel Target for Cancer Therapy |
| GSE23988_top8000 - GSE23988 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients (US samples) |
| GSE25065_top8000 - GSE25065 - SiGN-BN NNSR | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25066_top8000 - GSE25066 - SiGN-BN NNSR | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25136_top8000 - GSE25136 - SiGN-BN NNSR | Optimizing molecular signatures for prostate cancer recurrence |
| GSE25428_top8000 - GSE25428 - SiGN-BN NNSR | Gene expression profiles of ovarian cancer cell lines in the presence and absence of a DNA methyltransferase inhibitor |
| GSE2549_top8000 - GSE2549 - SiGN-BN NNSR | Malignant pleural mesothelioma |
| GSE2603_top8000 - GSE2603 - SiGN-BN NNSR | Subpopulations of MDA-MB-231 and Primary Breast Cancers |
| GSE26639_top8000 - GSE26639 - SiGN-BN NNSR | Expression Data from 226 patients of the REMAGUS02 trial |
| GSE26712_top8000 - GSE26712 - SiGN-BN NNSR | A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer |
| GSE27155_top8000 - GSE27155 - SiGN-BN NNSR | Human thyroid adenomas, carcinomas, and normals |
| GSE27480_top8000 - GSE27480 - SiGN-BN NNSR | Gene-expression analysis of Oncostatin-M (OSM) signalling in cervical squamous cell carcinomas over-expressing the Oncostatin-M receptor (OSMR) |
| GSE27562_top8000 - GSE27562 - SiGN-BN NNSR | Expression data from human PBMCs from breast cancer patients and controls |
| GSE2841_top8000 - GSE2841 - SiGN-BN NNSR | Expression Profiling of pheochromocytomas of various genetic origins |
| GSE28497_top8000 - GSE28497 - SiGN-BN NNSR | New markers for minimal residual disease detection in acute lymphoblastic leukemia |
| GSE2912_top8000 - GSE2912 - SiGN-BN NNSR | Molecular classification of multiple myeloma |
| GSE29354_top8000 - GSE29354 - SiGN-BN NNSR | Mesothelioma tumor gene expression profiles |
| GSE2990_top8000 - GSE2990 - SiGN-BN NNSR | Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis |
| GSE30929_top8000 - GSE30929 - SiGN-BN NNSR | Whole-transcript expression data for liposarcoma |
| GSE31245_top8000 - GSE31245 - SiGN-BN NNSR | Unique gene expression profile based upon pathologic response in epithelial ovarian cancer |
| GSE3143_top8000 - GSE3143 - SiGN-BN NNSR | Breast Cancer Dataset |
| GSE31547_top8000 - GSE31547 - SiGN-BN NNSR | MSKCC-A Primary Lung Cancer Specimens |
| GSE32269_top8000 - GSE32269 - SiGN-BN NNSR | Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer |
| GSE32448_top8000 - GSE32448 - SiGN-BN NNSR | CPDR tumor-benign 80 genechip dataset |
| GSE3593_top8000 - GSE3593 - SiGN-BN NNSR | Genomic approach to refine prognosis for adjuvant therapy in early stage non-small cell lung carcinoma |
| GSE3629_top8000 - GSE3629 - SiGN-BN NNSR | Molecular Marker for predicting development of cancer in ulcerative colitis |
| GSE3726_top8000 - GSE3726 - SiGN-BN NNSR | Prognostic gene signatures can be measured with samples stored in RNAlater |
| GSE5364_top8000 - GSE5364 - SiGN-BN NNSR | A Precisely Regulated Gene Expression Cassette Potently Modulates Metastasis and Survival in Multiple Solid Cancers |
| GSE5460_top8000 - GSE5460 - SiGN-BN NNSR | Predicting Features of Breast Cancer with Gene Expression Patterns |
| GSE5462_top8000 - GSE5462 - SiGN-BN NNSR | Letrozole (Femara) early response to treatment |
| GSE5846_top8000 - GSE5846 - SiGN-BN NNSR | NCI-60 Cancer Cell Line |
| GSE6008_top8000 - GSE6008 - SiGN-BN NNSR | Human ovarian tumors and normal ovaries |
| GSE6365_top8000 - GSE6365 - SiGN-BN NNSR | Distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma |
| GSE6401_top8000 - GSE6401 - SiGN-BN NNSR | Up-regulation of translational machinery and distinct genetic subgroups characterize hyperdiploidy in multiple myeloma |
| GSE6481_top8000 - GSE6481 - SiGN-BN NNSR | Gene Expression Analysis of Soft Tissue Sarcomas: Characterization & Reclassification of Malignant Fibrous Histiocytoma |
| GSE6764_top8000 - GSE6764 - SiGN-BN NNSR | Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma |
| GSE6791_top8000 - GSE6791 - SiGN-BN NNSR | Gene Expression Profiles of HPV-Positive and -Negative Head/Neck and Cervical Cancers |
| GSE7390_top8000 - GSE7390 - SiGN-BN NNSR | Strong Time Dependence of the 76-Gene Prognostic Signature |
| GSE7670_top8000 - GSE7670 - SiGN-BN NNSR | Expression data from Lung cancer |
| GSE7849_top8000 - GSE7849 - SiGN-BN NNSR | Age-Specific Differences of Oncogenic Pathway Deregulation Seen in Human Breast Tumors |
| GSE7904_top8000 - GSE7904 - SiGN-BN NNSR | Expression data from human breast tissue |
| GSE8057_top8000 - GSE8057 - SiGN-BN NNSR | Expression data from ovarian cancer cells with time-course and concentration-profiles |
| GSE8218_top8000 - GSE8218 - SiGN-BN NNSR | Gene expression data from prostate cancer samples |
| GSE9195_top8000 - GSE9195 - SiGN-BN NNSR | Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen |
| GSE9750_top8000 - GSE9750 - SiGN-BN NNSR | Identification of gene expression profiles in cervical cancer |
| GSE9936_top8000 - GSE9936 - SiGN-BN NNSR | Expression data from human breast cancer cells (MCF-7) coexpressing ERalpha and Erbeta, treated with phytoestrogens |
| GSE9992_top8000 - GSE9992 - SiGN-BN NNSR | Molecular and transcriptional characterization of chromosome 17p loss in chronic lymphocytic leukemia, experiment A |
(104 networks)
